Rezolute, Inc. (Nasdaq: RZLT) said the U.S. Food and Drug Administration is continuing to review data submitted from its Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE